Aspergillosis Treatment Market Size

Aspergillosis Treatment Market size was over USD 3.94 billion in 2024 and is set to exceed USD 6.98 billion by the end of 2037, growing at over 4.5% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of aspergillosis treatment is evaluated at USD 4.08 billion.

The increasing incidence of aspergillosis infections, specifically among immunocompromised people, is primarily pushing the demand for innovative treatment techniques. Moreover, Aspergillosis can pose as a life-threatening disease so the requirement for effective treatment is rising continuously. All across the world, almost 3,000,000 cases of chronic pulmonary aspergillosis, around 223,100 cases of cryptococcal meningitis complexing HIV/AIDs, roughly 700,000 cases of intrusive candidiasis, approximately 500,000 cases of Pneumocystis jirovecii pneumonia, almost 250,000 cases of intrusive aspergillosis are reported, yearly.

The medical technology developments and drug modification will further help the aspergillosis treatment market to hike in its anticipated CAGR in the coming years. Improvements in medical technology and drug development have taken to more focused and efficient therapies, modifying patient results and treatment efficiency. Antifungal drugs are primarily utilized to cure Aspergillosis. Voriconazole, an antifungal drug is extensively employed because of its fewer side effects and more efficiency in comparison to other drugs. In the most substantial studies encircling treatment of aspergillosis, voriconazole demonstrated about 30% entire mortality on day 84, with reports of feedback rates ranging between 36% and 52.8%. The starting implementation of voriconazole was related to reduced length of hospital keeping in a sub-group assessment of the TRANSNET population. Itraconazole or Amphotericin B also cures the aspergillosis infection successfully.